How much did Yuhan achieve in EBIT for the current year?
In the current year, Yuhan has achieved an EBIT of 110.77 B KRW.
Yuhan EBIT 2024
Yuhan EBIT
110.77 B KRW
Ticker
000100.KS
ISIN
KR7000100008
In 2024, Yuhan's EBIT was 110.77 B KRW, a 95.15% increase from the 56.76 B KRW EBIT recorded in the previous year.
The Yuhan EBIT history
| YEAR | EBIT (undefined KRW) |
|---|---|
| 2026e | 205.77 |
| 2025e | 178.47 |
| 2024e | 110.77 |
| 2023 | 56.76 |
| 2022 | 36.03 |
| 2021 | 48.6 |
| 2020 | 84.26 |
| 2019 | 12.54 |
| 2018 | 50.13 |
| 2017 | 88.71 |
| 2016 | 97.79 |
| 2015 | 85.84 |
| 2014 | 74.39 |
| 2013 | 61.84 |
| 2012 | 34.6 |
| 2011 | 52.73 |
| 2010 | 94.63 |
| 2009 | 86.35 |
| 2008 | 82.98 |
| 2007 | 71.64 |
| 2006 | 66.13 |
| 2005 | 72.73 |
| 2004 | 57.45 |
Yuhan Revenue, EBIT, Net Income KR7000100008 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Yuhan, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Yuhan from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Yuhan’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Yuhan. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Yuhan’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Yuhan’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Yuhan’s growth potential.
Yuhan Revenue, EBIT and net profit per share
| Date | Yuhan Revenue | Yuhan EBIT | Yuhan Net Income |
|---|---|---|---|
| 2026e | 2.39 T undefined | 205.77 B undefined | 216.72 B undefined |
| 2025e | 2.28 T undefined | 178.47 B undefined | 193.8 B undefined |
| 2024e | 2.11 T undefined | 110.77 B undefined | 148.32 B undefined |
| 2023 | 1.86 T undefined | 56.76 B undefined | 133.99 B undefined |
| 2022 | 1.78 T undefined | 36.03 B undefined | 93.68 B undefined |
| 2021 | 1.69 T undefined | 48.6 B undefined | 100.85 B undefined |
| 2020 | 1.62 T undefined | 84.26 B undefined | 189.2 B undefined |
| 2019 | 1.48 T undefined | 12.54 B undefined | 39.22 B undefined |
| 2018 | 1.52 T undefined | 50.13 B undefined | 56.31 B undefined |
| 2017 | 1.46 T undefined | 88.71 B undefined | 106.71 B undefined |
| 2016 | 1.32 T undefined | 97.79 B undefined | 157.63 B undefined |
| 2015 | 1.13 T undefined | 85.84 B undefined | 123.22 B undefined |
| 2014 | 1.02 T undefined | 74.39 B undefined | 89.12 B undefined |
| 2013 | 943.61 B undefined | 61.84 B undefined | 84.86 B undefined |
| 2012 | 776.46 B undefined | 34.6 B undefined | 79.25 B undefined |
| 2011 | 679.23 B undefined | 52.73 B undefined | 92.4 B undefined |
| 2010 | 663.57 B undefined | 94.63 B undefined | 127.58 B undefined |
| 2009 | 646.77 B undefined | 86.35 B undefined | 118.97 B undefined |
| 2008 | 611.19 B undefined | 82.98 B undefined | 122.64 B undefined |
| 2007 | 493.29 B undefined | 71.64 B undefined | 89.76 B undefined |
| 2006 | 422.48 B undefined | 66.13 B undefined | 65.23 B undefined |
| 2005 | 401.79 B undefined | 72.73 B undefined | 61.24 B undefined |
| 2004 | 345.53 B undefined | 57.45 B undefined | 50.58 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 345.53 B KRW | 57.45 B KRW | 50.58 B KRW |
| 2005 | 401.79 B KRW | 72.73 B KRW | 61.24 B KRW |
| 2006 | 422.48 B KRW | 66.13 B KRW | 65.23 B KRW |
| 2007 | 493.29 B KRW | 71.64 B KRW | 89.76 B KRW |
| 2008 | 611.19 B KRW | 82.98 B KRW | 122.64 B KRW |
| 2009 | 646.77 B KRW | 86.35 B KRW | 118.97 B KRW |
| 2010 | 663.57 B KRW | 94.63 B KRW | 127.58 B KRW |
| 2011 | 679.23 B KRW | 52.73 B KRW | 92.4 B KRW |
| 2012 | 776.46 B KRW | 34.6 B KRW | 79.25 B KRW |
| 2013 | 943.61 B KRW | 61.84 B KRW | 84.86 B KRW |
| 2014 | 1.02 T KRW | 74.39 B KRW | 89.12 B KRW |
| 2015 | 1.13 T KRW | 85.84 B KRW | 123.22 B KRW |
| 2016 | 1.32 T KRW | 97.79 B KRW | 157.63 B KRW |
| 2017 | 1.46 T KRW | 88.71 B KRW | 106.71 B KRW |
| 2018 | 1.52 T KRW | 50.13 B KRW | 56.31 B KRW |
| 2019 | 1.48 T KRW | 12.54 B KRW | 39.22 B KRW |
| 2020 | 1.62 T KRW | 84.26 B KRW | 189.2 B KRW |
| 2021 | 1.69 T KRW | 48.6 B KRW | 100.85 B KRW |
| 2022 | 1.78 T KRW | 36.03 B KRW | 93.68 B KRW |
| 2023 | 1.86 T KRW | 56.76 B KRW | 133.99 B KRW |
| 2024e | 2.11 T KRW | 110.77 B KRW | 148.32 B KRW |
| 2025e | 2.28 T KRW | 178.47 B KRW | 193.8 B KRW |
| 2026e | 2.39 T KRW | 205.77 B KRW | 216.72 B KRW |
Yuhan stock margins KR7000100008 ·
The Yuhan margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Yuhan. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Yuhan.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Yuhan's sales revenue. A higher gross margin percentage indicates that the Yuhan retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Yuhan's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Yuhan's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Yuhan's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Yuhan. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Yuhan's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Yuhan Margin History
| Yuhan Gross margin | Yuhan Profit margin | Yuhan EBIT margin | Yuhan Profit margin |
|---|---|---|---|
| 2026e | 30.44 % | 8.61 % | 9.07 % |
| 2025e | 30.44 % | 7.84 % | 8.52 % |
| 2024e | 30.44 % | 5.24 % | 7.02 % |
| 2023 | 30.44 % | 3.05 % | 7.21 % |
| 2022 | 29.18 % | 2.03 % | 5.28 % |
| 2021 | 31.08 % | 2.88 % | 5.98 % |
| 2020 | 34.47 % | 5.2 % | 11.68 % |
| 2019 | 29.1 % | 0.85 % | 2.65 % |
| 2018 | 27.24 % | 3.3 % | 3.71 % |
| 2017 | 29.04 % | 6.07 % | 7.3 % |
| 2016 | 29.49 % | 7.4 % | 11.93 % |
| 2015 | 30.18 % | 7.6 % | 10.92 % |
| 2014 | 31 % | 7.31 % | 8.76 % |
| 2013 | 31.13 % | 6.55 % | 8.99 % |
| 2012 | 31.63 % | 4.46 % | 10.21 % |
| 2011 | 37.25 % | 7.76 % | 13.6 % |
| 2010 | 41.69 % | 14.26 % | 19.23 % |
| 2009 | 44.73 % | 13.35 % | 18.39 % |
| 2008 | 47.65 % | 13.58 % | 20.07 % |
| 2007 | 49.38 % | 14.52 % | 18.2 % |
| 2006 | 50.42 % | 15.65 % | 15.44 % |
| 2005 | 52.57 % | 18.1 % | 15.24 % |
| 2004 | 46.41 % | 16.63 % | 14.64 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 46.41 % | 16.63 % | 14.64 % |
| 2005 | 52.57 % | 18.1 % | 15.24 % |
| 2006 | 50.42 % | 15.65 % | 15.44 % |
| 2007 | 49.38 % | 14.52 % | 18.2 % |
| 2008 | 47.65 % | 13.58 % | 20.07 % |
| 2009 | 44.73 % | 13.35 % | 18.39 % |
| 2010 | 41.69 % | 14.26 % | 19.23 % |
| 2011 | 37.25 % | 7.76 % | 13.6 % |
| 2012 | 31.63 % | 4.46 % | 10.21 % |
| 2013 | 31.13 % | 6.55 % | 8.99 % |
| 2014 | 31 % | 7.31 % | 8.76 % |
| 2015 | 30.18 % | 7.6 % | 10.92 % |
| 2016 | 29.49 % | 7.4 % | 11.93 % |
| 2017 | 29.04 % | 6.07 % | 7.3 % |
| 2018 | 27.24 % | 3.3 % | 3.71 % |
| 2019 | 29.1 % | 0.85 % | 2.65 % |
| 2020 | 34.47 % | 5.2 % | 11.68 % |
| 2021 | 31.08 % | 2.88 % | 5.98 % |
| 2022 | 29.18 % | 2.03 % | 5.28 % |
| 2023 | 30.44 % | 3.05 % | 7.21 % |
| 2024e | 30.44 % | 5.24 % | 7.02 % |
| 2025e | 30.44 % | 7.84 % | 8.52 % |
| 2026e | 30.44 % | 8.61 % | 9.07 % |
Yuhan Aktienanalyse
What does Yuhan do?
The Yuhan Corporation is a South Korean conglomerate that was founded on September 1, 1926, under the name "Chosun Pharmaceutical Company". The company is headquartered in Seoul and employs more than 5,000 people worldwide. History: The Yuhan Corporation started as a small company with a single product, a fish oil-based ointment called "Yuksundo". The company worked hard to improve its products and expand its market, eventually expanding into other business areas such as the production of antibiotics and diabetes treatments. In the early 1950s, the company also ventured into the research and development of other pharmaceuticals. In 1962, Yuhan became a publicly traded company and received a variety of awards in the following years, including several Korean Industrial Awards. Since its inception, the company has remained committed to improving people's lives through innovation and science. Business model: The Yuhan Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of drugs and other health products. The company also makes investments in innovative technologies and healthcare startups. Over the years, Yuhan has expanded its business through partnerships with other companies and acquisitions of companies such as LGL Holdings and SillaJen Inc. The company also engages in international business relations, such as selling its products and medications in other countries. Divisions: The Yuhan Corporation has four main business divisions: Medical Research and Development, Drug Manufacturing, Biotechnology Product Development, and Health Product Production. The first division is coordinated by Yuhan Research & Development Co. Ltd, while drug manufacturing is done by Yuhan Manufacturing Co. Ltd. Biotechnology is done by Yuhan Biomedical Research Institute, and the health product segment is handled by Yuhan Healthcare. Products: Yuhan's products are diverse and include a wide range of drugs and health products. The company is involved in the production of antibiotics, analgesics, vein treatment agents, diabetes medications, cardiovascular drugs, and other pharmaceutical products. Other products also include cosmetics, oral care products, and dermatology drugs. Some of Yuhan's well-known products include the antibiotic Ceclor, a medication for the treatment of diabetes and metabolic disorders, as well as apple-based cosmetic products. All Yuhan products are manufactured according to strict quality standards and are known for their effectiveness and safety. Conclusion: The Yuhan Corporation has evolved into a diverse and innovative company focused on the production of drugs and health products. The company has a long history with many successes and has established itself as one of the major forces in the South Korean economy over the past decades. Yuhan's mission to create better healthcare remains as relevant today as it was at the time of its founding. Yuhan ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Yuhan's EBIT
Yuhan's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Yuhan's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Yuhan's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Yuhan’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Yuhan stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Yuhan.
How has the EBIT of Yuhan developed in recent years?
The EBIT of Yuhan has increased by 95.152% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Yuhan?
The EBIT of Yuhan is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Yuhan pay?
Over the past 12 months, Yuhan paid a dividend of 428.57 KRW . This corresponds to a dividend yield of about 0.29 %. For the coming 12 months, Yuhan is expected to pay a dividend of 443.36 KRW.
What is the dividend yield of Yuhan?
The current dividend yield of Yuhan is 0.29 %.
When does Yuhan pay dividends?
Yuhan pays a quarterly dividend. This is distributed in the months of January, January, January, January.
How secure is the dividend of Yuhan?
Yuhan paid dividends every year for the past 23 years.
What is the dividend of Yuhan?
For the upcoming 12 months, dividends amounting to 443.36 KRW are expected. This corresponds to a dividend yield of 0.3 %.
In which sector is Yuhan located?
Yuhan is assigned to the 'Health' sector.
Wann musste ich die Aktien von Yuhan kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Yuhan from 5/1/2024 amounting to 428.571 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.
When did Yuhan pay the last dividend?
The last dividend was paid out on 5/1/2024.
What was the dividend of Yuhan in the year 2023?
In the year 2023, Yuhan distributed 380.952 KRW as dividends.
In which currency does Yuhan pay out the dividend?
The dividends of Yuhan are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Yuhan
Our stock analysis for Yuhan Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Yuhan Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
